Correction: Investors Hope for Rate Cut Following Subdued Inflation as US Futures Mixed in Friday's Premarket Session

(Corrects the third paragraph to note the personal income and outlays report being rescheduled.)

US stock futures were mixed in Friday's premarket session, with investors hopeful of a federal rate cut following lower-than-expected US inflation data released Thursday.

The Dow Jones Industrial Average futures were off 0.09%, S&P 500 futures were up 0.04%, and Nasdaq futures were moving 0.09% higher.

The Core Personal Consumption Expenditure Price Index report tracking changes in the price of goods and services bought by consumers, excluding food and energy, was originally set for release later today but has been rescheduled by the US Bureau of Economic Analysis.

Existing home sales figures for November will be announced later in the morning, with analysts surveyed by Bloomberg expecting annual sales to rise to 4.15 million from 4.10 million in October.

Oil prices were moving higher, with front-month global benchmarks Brent crude and West Texas Intermediate crude rising 0.8% and 0.7% respectively.

In equities, shares of Vision Marine Technologies (VMAR) surged 22% in Friday's premarket session, offsetting nearly half of its losses from Thursday.

Psyence Biomedical (PBM) shares climbed 10% after it said Friday that the Bellberry Human Research Ethics Committee has approved the use of its psilocybin product in a phase 2b trial evaluating psilocybin-assisted psychotherapy for Adjustment Disorder in cancer patients.

And WhiteFiber's (WYFI) stock was 20% higher after the company said overnight its subsidiary, Enovum Data Centers, signed a 10-year, 40-megawatt colocation deal with Nscale Global at the NC-1 data center in Madison, North Carolina.

On the losing side, shares of cbdMD (YCBD) tumbled 14% ahead of its Q4 and fiscal 2025 earnings call after the markets close Friday.

Cassava Sciences (SAVA) dropped 13% after it said Friday that the US Food and Drug Administration confirmed that its proposed clinical trial of simufilam to treat tuberous sclerosis complex-related epilepsy is on "full clinical hold."

And shares of Mega Fortune (MGRT) fell 6%, adding to a 33% loss on Thursday.